Holos Life Sciences
Latest round
- Series A
Last raised
- Nov 2018
Total raised
- $1.8M
Investors
- 2
About Holos Life Sciences
Based in Singapore, and established in 2016, Holos Life Sciences is a biotechnology company that focuses on the epigenome biomarker field. It has additional branches in Singapore, Australia, and the UK. Dr. Alexandre Akoulitchev, and Dr. Peter Fricker, the company's founders, are investment professionals. Dr. Alexandre Akoulitchev, the company's chief scientific advisor, majored in cell biology and graduated from University College London. Holos Life Sciences focuses on R&D of biomarkers for the non-disease state, using the platform EpiSwitch™ developed by Oxford Biodynamics Plc. EpiSwitch™ can discover 3D genomics at scale, and identify chromosome conformation signature biomarkers. The biomarkers have predictive, diagnostic, and prognostic values. The biomarkers can be used for developing human personalized healthcare.
Who invested in Holos Life Sciences
2 investors across 1 round
See all investors in Holos Life Sciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 30, 2018
Amount
$1.8M
Investors
Questions about Holos Life Sciences
Who invested in Holos Life Sciences?
Holos Life Sciences has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Holos Life Sciences raised?
Holos Life Sciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Holos Life Sciences last raise money?
Holos Life Sciences's most recent round on record is a Series A, in Nov 2018.
What does Holos Life Sciences do?
Based in Singapore, and established in 2016, Holos Life Sciences is a biotechnology company that focuses on the epigenome biomarker field.
Where is Holos Life Sciences headquartered?
Holos Life Sciences is headquartered in Singapore.
Which VCs invest in companies like Holos Life Sciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Holos Life Sciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Holos Life Sciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.